Related Experiment Video
Updated: Jul 15, 2026
10:29
Applying Fluorescence Resonance Energy Transfer (FRET) to Examine Effector Translocation Efficiency by Coxiella burnetii during siRNA Silencing
Published on: July 6, 2016
Erufosine: a membrane targeting antineoplastic agent with signal transduction modulating effects
M M Zaharieva1, S M Konstantinov, B Pilicheva
1Laboratory for Molecular Pharmacology and Experimental Chemotherapy, Department of Pharmacology and Toxicology, Medical University of Sofia, 2 Dunav Street, 1000 Sofia, Bulgaria. zaharieva26@yahoo.com
Annals of the New York Academy of Sciences
|April 4, 2007
Summary
Erufosine, an ether lipid analog, shows synergistic effects with imatinib mesylate in chronic myeloid leukemia (CML) cells. This combination therapy, targeting CML, may benefit relapsed patients by modulating key proteins like retinoblastoma protein (Rb).
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Erufosine (erucylphospho-N,N,N,-trimethylpropylammonium, ErPC3) is an alkylphosphocholine (APC) with demonstrated activity against leukemic cells.
- The precise mechanism of action for erufosine, particularly in combination therapies, remains incompletely understood.
- Chronic myeloid leukemia (CML) often develops resistance to existing treatments, necessitating novel therapeutic strategies.
Purpose of the Study:
- To investigate the synergistic effects of erufosine in combination with imatinib mesylate against CML cell lines.
- To elucidate the molecular mechanisms underlying the observed synergistic effects, focusing on protein signaling pathways and cell cycle regulators.
- To evaluate the potential of this combination therapy for treating drug-resistant CML.
Main Methods:
- Utilized K-562 and BV-173 CML cell lines for in vitro studies.
- Administered consecutive treatments of erufosine and imatinib mesylate at varying concentrations.
- Assessed synergistic effects using the MTT-dye reduction assay and analyzed protein expression (Rb, PKB/Akt, pAkt, p27, BCR-ABL) via Western blot.
Main Results:
- Consecutive treatment with erufosine and imatinib mesylate demonstrated synergistic cytotoxicity in K-562 and BV-173 cells.
- Erufosine treatment led to decreased expression of pAkt and BCR-ABL, while inducing retinoblastoma protein (Rb) expression and increasing p27 levels.
- Observed alterations in protein signaling pathways, including Rb induction, suggest a role in the synergistic drug interaction.
Conclusions:
- The combination of erufosine and imatinib mesylate exhibits significant synergistic activity against CML cell lines.
- Erufosine's mechanism involves modulation of protein signaling, notably the induction of Rb, contributing to its anti-leukemic effects.
- This combination therapy holds promise as a potential treatment strategy for relapsed or drug-resistant CML patients.
More Related Videos
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:31Transducer Mechanism: Nuclear Receptors
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:30siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...